A 57-Year-Old Man with Nonmetastatic Castration-Resistant Disease

Matthew R. Smith, MD, PhD introduces a nonmetastatic castration-resistant prostate cancer (CRPC) patient case featuring a 52-year-old man referred to urology with a PSA of 6.8 ng/mL.

Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.

Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.

Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.